Ergoteles’s ADMA Biologics ADMA Stock Holding History

Ergoteles’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,462	Closed	-$71.8K	–	38
2023 Q2	$71.8K	Buy	+19,462	New	+$72.1K	﹤0.01%	934
2022 Q2	–	Sell	-71,400	Closed	-$131K	–	1601
2022 Q1	$131K	Buy	+71,400	New	+$111K	0.01%	1077
2021 Q3	–	Sell	-299,500	Closed	-$479K	–	1150
2021 Q2	$479K	Buy	+299,500	New	+$527K	0.01%	826
2021 Q1	–	Sell	-30,100	Closed	-$59K	–	768
2020 Q4	$59K	Buy	+30,100	New	+$63.3K	﹤0.01%	638

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ergoteles's ADMA Position: Q3 2023 in Review

Ergoteles sold out of ADMA Biologics (ADMA) in Q3 2023, closing a stake of 19,462 shares — an estimated $71.8K sold.

Ergoteles first reported a position in ADMA in Q4 2020 and held it in 4 quarters. The position peaked at $479K in Q2 2021. 188 funds tracked by Wall St. Rank hold ADMA as of Q3 2023.

Ergoteles reported no remaining ADMA Biologics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 19,462 ADMA Biologics shares in Q3 2023, an estimated $71.8K.
Ergoteles first reported a position in ADMA Biologics in Q4 2020 and held it in 4 quarters.
Ergoteles's ADMA Biologics position peaked at $479K in Q2 2021.
188 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.